Champions Oncology (CSBR) Q1 FY27 earnings call

Champions Oncology delivered strong Q1 FY27 results, demonstrating the payoff from prior investments with significant revenue growth and margin expansion across both its translational oncology services and data licensing businesses. The company achieved its fifth consecutive quarter of positive adjusted EBITDA, driven by operational discipline and in-house cost efficiencies. Management remains encouraged by the robust pipeline and strategic strengthening of its data offerings, with a focus on continued profitability improvement.